Exact Sciences CORP 8-K filings

Exact Sciences Corporation has finalized its merger with Abbott Laboratories, becoming a direct wholly-owned subsidiary of Abbott.

Exact Sciences Corporation has received all regulatory approvals for its merger with Abbott Laboratories, with closing anticipated on March 23, 2026.

Exact Sciences Corporation announced record fourth quarter and full year 2025 financial results, driven by strong growth in Screening and Precision Oncology revenue, alongside significant advancements in its cancer diagnostic pipeline and progress towards its merger with Abbott Laboratories.

Exact Sciences Corporation accelerates 2025 annual bonuses and vests certain equity awards for its named executive officers to mitigate potential tax impacts related to its pending merger with Abbott Laboratories.

Abbott Laboratories will acquire Exact Sciences for $105 per share in cash, totaling $21 billion, to become a leader in the rapidly growing cancer screening and precision oncology diagnostics market.

Exact Sciences announced record third-quarter 2025 revenue of $851 million, a 20% increase, and raised its full-year 2025 guidance, driven by strong performance in its Screening and Precision Oncology segments and the launch of its Cancerguard test.

Exact Sciences announced record second-quarter 2025 revenue, improved adjusted EBITDA, and raised full-year guidance, alongside a strategic collaboration with Freenome for blood-based colorectal cancer screening.

Exact Sciences Corporation announced that its shareholders approved the 2025 Omnibus Long-Term Incentive Plan, an amendment to the 2010 Employee Stock Purchase Plan, and the re-election of all seven director nominees at its 2025 Annual Meeting.

Exact Sciences reported an 11% increase in first-quarter revenue, driven by strong performance in screening and precision oncology, and raised its full-year 2025 revenue and adjusted EBITDA guidance.

Exact Sciences Corporation appoints Leslie Trigg to its Board of Directors, filling the vacancy left by Kathleen Sebelius' retirement.

Exact Sciences reports a 10% increase in total revenue for both the fourth quarter and full year 2024, alongside plans to launch three new cancer tests in 2025.

Exact Sciences anticipates total fourth quarter revenue of $713 million and plans to launch three new cancer tests in 2025.

Exact Sciences Corporation has appointed Kim Popovits to its Board of Directors, increasing the board size from nine to ten members.

Exact Sciences announced record revenue and cash flow for the third quarter of 2024, along with FDA approval for its next-generation Cologuard Plus test, while also updating its full-year revenue and adjusted EBITDA guidance.

Exact Sciences announced record second-quarter revenue of $699 million and raised its full-year adjusted EBITDA guidance.

Exact Sciences Corporation held its 2024 Annual Meeting of Shareholders on June 13, 2024, where shareholders elected three directors, ratified the appointment of PricewaterhouseCoopers as the independent auditor, and approved executive compensation.

Exact Sciences is reorganizing its commercial operations under its Screening and Precision Oncology teams and has announced the departure of its Chief Commercial Officer, while reaffirming its financial outlook for 2024.

Exact Sciences has filed a prospectus supplement to register the resale of up to 5.57 million shares of its common stock by existing selling stockholders.

Exact Sciences announced a 6% increase in total revenue for the first quarter of 2024, reaching $638 million, and reaffirmed its full-year revenue and adjusted EBITDA guidance.

Dr. Freda Lewis-Hall will retire from the Exact Sciences Corporation Board of Directors after the 2024 annual shareholder meeting for personal reasons.

Exact Sciences Corporation finalized a debt exchange, issuing $620.7 million in new convertible senior notes due 2031 in exchange for existing notes and cash.

Exact Sciences has appointed Aaron Bloomer as its new Chief Financial Officer, effective May 15, 2024, bringing extensive financial leadership experience from Baxter International and 3M.

Exact Sciences announced record fourth-quarter and full-year 2023 revenue, positive free cash flow, and provided a strong revenue outlook for 2024.